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Abstract
Huntington’s disease (HD) is a genetic disease caused by a
CAG trinucleot ide repeat expansion encoding a
polyglutamine tract in the huntingtin (HTT) protein, ultimate-
ly leading to neuronal loss and consequent cognitive decline
and death. As no treatments for HD currently exist, several
chemical screens have been performed using cell-based
models of mutant HTT toxicity. These screens measured sin-
gle disease-related endpoints, such as cell death, but had low
‘hit rates’ and limited dimensionality for therapeutic detection.
Here, we have employed gene expression microarray analysis
of HD samples—a snapshot of the expression of 25,000
genes—to define a gene expression signature for HD from
publically available data. We used this information to mine a
database for chemicals positively and negatively correlated to
the HD gene expression signature using the Connectivity
Map, a tool for comparing large sets of gene expression pat-
terns. Chemicals with negatively correlated expression pro-
files were highly enriched for protective characteristics against
mutant HTT fragment toxicity in in vitro and in vivo models.
This study demonstrates the potential of using gene expres-
sion to mine chemical activity, guide chemical screening, and
detect potential novel therapeutic compounds.
Key messages
& Single-endpoint chemical screens have low therapeutic
discovery hit-rates.
& In the context of HD, we guided a chemical screen using
gene expression data.
& The resulting chemicals were highly enriched for suppres-
sors of mutant HTT fragment toxicity.
& This study provides a proof of concept for wider usage in
all chemical screening.
Keywords Huntington’s . Huntingtin . ConnectivityMap .
cMap . Chemical screening . Therapeutic detection
Introduction
Huntington’s disease (HD) is a neurodegenerative disease
caused by a polyglutamine (polyQ) expansion in the
huntingtin (HTT) protein [1]. HD is characterized by mood
and cognitive impairments, motor dysfunction (including cho-
rea) and, ultimately, death [2]. The molecular mechanisms
underlying the cellular toxicity of mutant HTTare not entirely
clear. However, both the loss of normal HTT function and the
toxic gain of function of the mutant HTT protein are thought
to be important in HD progression [3, 4]. A number of path-
ological mechanisms have been implicated in the onset and
progression of HD, including mitochondrial dysfunction [5],
neurotrophic factor deprivation [6], and excitotoxicity [7].
One of the most studied characteristics of mutant HTT is its
propensity to form stable inclusions or aggregates [8]. These
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inclusions have been implicated in activating cellular stress
mechanisms such as ER stress [9] and may play a role in
protecting cells from mutant HTT-induced cell death [10].
Current evidence suggests that soluble mutant HTToligomers
produced early in the aggregation process are the major cause
of HD neuropathology [11], and these have been shown to
affect mitochondrial function [12]. However, mutant HTT ag-
gregates can sequester a number of transcription factors which
contain polyQ-rich regions—such as CBP [13], TBP [14] and
SP1 [15]—both in the nucleus and in the cytoplasm.
Sequestration of these proteins reduces the pool of transcrip-
tion factors available to activate/repress their target genes [16],
manifesting in transcriptional dysregulation that has been ex-
tensively characterized in human samples [17], in vivo [18,
19] and in vitro models [20, 21].
No drugs are currently available for delaying disease onset
or progression in HD. In order to identify chemicals that might
interfere with the molecular mechanisms of mutant HTT tox-
icity and prevent neurodegeneration, various high-throughput
chemical screens have been performed in yeast [22], mamma-
lian cells [23, 24] and cell-free assays [25]. In general, these
screens have tested chemical libraries containing hundreds to
thousands of chemicals for their effects on either aggregation
of amino-terminal fragments of mutant HTT—which contain
the polyQ stretch—or cellular apoptosis resulting from ex-
pression of these mutant HTT fragments. While such screens
have identified benzothiazoles [25] and mTOR inhibitors [22]
as potential therapeutic agents, these approaches have not yet
been successfully translated to human therapies. One under-
lying issue may be the oversimplified nature of the screens,
which focus on single endpoints.
We sought to identify chemicals that ameliorate mutant
HTT fragment toxicity using gene expression signature-
based chemical screening. Such approaches use a transcription
pattern to describe a biological condition. By finding similar-
ities and differences between the transcription patterns of var-
ious biological conditions, one can develop hypotheses re-
garding the similarities and differences of the biological con-
ditions themselves. This approach has been used extensively
in the cancer field to distinguish between cancer subtypes
[26]. Linking chemical activity with gene expression has been
demonstrated in yeast [27, 28], where compendiums of gene
expression data for around 100 chemicals were created and
hierarchical clustering used to group similar chemicals togeth-
er with some success. More recently, chemical treatments in
human cell lines were used to create a database for the
Connectivity Map (cMap) [29]. The cMap is a technique
which employs a transcriptional profile of interest to mine a
database of gene expression data from 1600 chemical treat-
ments and returns a measure of positive or negative similarity
to each chemical as an output. By identifying similarities be-
tween the transcription patterns produced by different
chemicals, functional similarities can be identified between
those compounds. The major advantage of this approach is
that this requires no prior understanding of the underlying
biological processes at play, and is therefore unbiased. The
initial aim of the cMap was to connect chemicals and diseases
via similar transcriptional patterns. However, there are as yet
few examples where a transcriptional pattern for a disease has
been used as a ‘target’ for predicting potential therapeutic
agents. The most notable employed a transcription pattern
from fasting muscle tissue to identify urosolic acid as an in-
hibitor of skeletal muscle atrophy [30].
Transcriptional dysregulation in HD is well documented,
making this disorder a particularly good paradigm for testing
the disease relevance of the cMap technique. Using gene ex-
pression profiling data from humanHDbrains [17], we used the
cMap to identify chemicals that induced positive (similar) or
negative (inverse) transcriptional patterns to that of HD in an
unbiased manner. The predicted chemicals were subsequently
screened for neuroprotection in well-established acute mamma-
lian cell and Drosophila models of HD that have previously
been employed to detect chemicals that protect against mutant
HTT toxicity [23, 31]. These HTT fragment-based models are
well suited to chemical screening due to the rapid manifestation
of a broad range of disease-relevant phenotypes with mecha-
nistic relevance to HD [32], though they may not capture some
disease phenotypes dependent upon full-length HTT protein.
Using this approach, we identified an enriched list of com-
pounds that ameliorate disease phenotypes in mammalian cell
andDrosophilamodels of mutant HTT fragment toxicity, all of
which produce an opposite transcription pattern to that ob-
served in the HD patient samples. Positively correlated
chemicals had no effect and served as an integrated control.
These data provide a proof of concept and highlight the promise
of the cMap for uncovering novel therapeutic strategies.
Methods
Tissue culture
PC12 cells stably transfected with a ponasterone A-inducible
mutant HTT fragment (103Q) (first 17 amino acids of HTT plus
polyQ repeat fusedwith green fluorescent protein (GFP); referred
to as HTT103Q in the text)—known as the Htt14A2.5 cell line
(Apostol et al. 2003)—weremaintained and passaged in DMEM
supplemented with 10 % horse serum (v/v), 5 % FCS (v/v) with
2 mM GlutaMax and 1 mM sodium pyruvate in T75 flasks
(Greiner, UK) and incubated at 37 °C in a 5 % CO2 atmosphere.
Drosophila husbandry, compound feeding and assays
Flies were maintained in standard maize food at 25 °C in light/
dark cycle of 12:12. The elavGAL4 [c155] fly stocks was
obtained from the Bloomington Stock Center (Bloomington,
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IN). The HTT93Q line was a gift from LarryMarsh and Leslie
Thompson [57]. Crosses were set up between male flies car-
rying elavGAL4 driver and virgin females carrying the
HTT93Q transgene. In the F1 generation only females
expressed the HTT93Q, while males were used as controls.
Fly treatment, cell viability, caspase induction, aggregate
counting and statistical analyses are described in the
Supplementary Material.
Results
Connectivity mapping identifies chemicals predicted
to modulate HD phenotypes
HD neuropathology has been classified using a grading sys-
tem devised by Vonsattel et al. [33], which defines five grades
of pathology (0–4) in increasing order of severity. We obtain-
ed gene expression data for several brain regions (frontal lobe,
cerebellum, caudate nucleus) fromHD patients at all Vonsattel
grades, as well as age- and sex-matched control samples [17]
from ArrayExpress (www.ebi.ac.uk/arrayexpress). HD
samples were compared with age- and sex-matched controls,
and significant gene expression changes were used to generate
a heatmap to visually compare the regional and pathological
alterations (Fig. 1a). This approach found the greatest amount
of transcriptional dysregulation occurs in the caudate nucleus
compared to other regions. We found that while the genes
dysregulated across grades 0–2 are very similar, the degree
of dysregulation increases with increasing Vonsattel grade,
as originally described [17]. In order to use samples with a
robust gene expression changes, we chose data from the cau-
date nucleus at grade 2 to generate a gene signature for HD.
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Fig. 1 Using the Connectivity Map to identify chemicals with positive
and negative connections to HD. a Vonsattel graded caudate nucleus,
cerebellum, and frontal lobe from patients with HD were compared
with age and sex-matched controls. HD-induced transcriptional dysregu-
lation is most profound in the caudate nucleus, and transcriptional dys-
regulation increases with increasing Vonsattel grade. Genes not deemed
significantly changed in any control/HD comparison were removed. The
resulting gene matrix was hierarchically clustered using a Euclidian
distance algorithm. b A gene signature for HD produces strong positive
and negative connections with several chemicals. The top 100 most
changed genes in the caudate nucleus grade 2 samples, selected by abso-
lute fold change, were used to query the cMap gene expression database
(Build 2). The top 12 most highly positively and negatively correlated
chemicals were selected for further testing, where +1 and −1 represent a
perfect positive or negative match, respectively
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changes linked with the gross pathological events found at
later stages of the disease (grades 3 and 4). We selected the
most dysregulated differentially expressed genes (DEGs) by
absolute fold change, creating a 100 gene signature to query
the cMap for chemicals that produced positive or negative
gene expression patterns (Table S1). The highest scoring pos-
itive and negative connections were identified (a linear scor-
ing system where +1 and −1 represent a perfect positive and
negative correlation, respectively), with 12 in each category
selected for downstream testing (Fig. 1b). Notably, these can-
didate chemicals represented a diverse set of pharmacological
classes, including endogenous hormones (estradiol), PI3K-
inhibitors (LY294002), β-blockers (nadolol), metal chelators
(deferoxamine) and metabolic inhibitors (oligomycin).
Inversely connected chemicals reduce mutant
HTT-induced caspase activation
We next used a luminescent caspase-activation assay to assess
whether any of the chemicals with positively or negatively
correlated signatures modulated mutant HTT-induced apopto-
sis in a PC12 cell line which inducibly expresses an N-
terminal mutant HTT fragment (HTT103Q), which we and
others have previously employed [20, 31]. A range of sub-
cytotoxic concentrations, determined byMTS cellular toxicity
assays (Fig. S1), were added simultaneously with the induc-
tion of HTT103Q expression, and caspase 3/7 activation was
measured after 72 h, a point at which substantial caspase 3/7
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Fig. 2 Negatively correlated
chemicals ameliorate mutant HTT
fragment toxicity in PC12 cells. a
Caspase activity measurements
for chemical screening were
carried out at 72 h post-
HTT103Q-induction as caspase
activity peaks at this time point. b
All test plates contained a 10 μM
ebselen treatment. Ebselen is
known to prevent caspase 3/7
cleavage post HTT103Q
induction, and therefore served as
a positive control [31]. c
Chemicals that induce gene
expression changes that positively
correlate with HD have no
significant effect on caspase 3/7
activation in PC12 cells
expressing HTT103Q. d Seven of
the 12 selected chemicals that
induce gene expression changes
which were negatively correlated
with HD reduce HTT103Q
toxicity in PC12 cells. PC12 cells
expressing HTT103Q were
exposed to sub-cytotoxic
concentrations of chemicals for
72 h. Mean±SEM (N=3).
*P<0.05, **P<0.01,
***P<0.001
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antioxidant ebselen was included on every plate as a positive
control [31] (Fig. 2a). Chemicals with positively correlated
expression signatures had very little effect on caspase activa-
tion over the 72-h incubation period (Fig. 2c). Piperine pro-
duced a reduction in caspase activation; however, this was due
to the highest concentration being close to the cytotoxic win-
dow (Fig. S1). In contrast, 7 of the 12 chemicals with nega-
tively correlated signatures significantly reduced HTT103Q-
induced caspase activation (Fig. 2d). Chlorzoxazone, copper
sulphate, deferoxamine, felbinac, oligomycin and primidone
all reduced caspase activation in a dose-dependent manner.
These chemicals were subsequently selected for further
investigation.
Deferoxamine and oligomycin reduce mutant HTT
inclusion body formation
Mutant HTT aggregation is an important early, upstream pro-
cess in the development of HD. To gain mechanistic insight
into whether the protective chemicals modulated HTT103Q
inclusion body formation, we employed a robust
fluorescence-based mutant HTT aggregation assay in living
cells. A Cellomics Arrayscan High Content Screening system
with an aggregate counting algorithm was used to quantify
GFP-tagged HTT103Q aggregates in the PC12 cell model of
mutant HTT fragment toxicity described above (Fig. 3a).
Predefined concentrations of the chemicals which displayed
a)
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aggregation in PC12 cells using
Cellomics imaging technology.
PC12 cells expressing GFP-
tagged HTT103Q were stained
with Hoechst stain to visualize the
nucleus. A Cellomics ‘spotcount’
algorithm was used to identify
cell nuclei, estimate cell
boundaries, detect intracellular
HTT103Q aggregates and record
their intensity. b PC12 cells
express HTT103Q extensively
following induction with
ponasterone A, detected by GFP
signal, and stable HTT103Q
aggregates form in the cells. A
time point of 48 h was used for
further experiments as it allowed





induction and exposure to
deferoxamine or oligomycin. d
Deferoxamine and oligomycin
reduce HTT103Q aggregation in
PC12 cells. PC12 cells expressing
GFP-tagged HTT103Q were
exposed to chemicals that reduced
caspase 3/7 activation for 48 h.
The cells were fixed, Hoechst
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significant dose–response relationships in the caspase 3/7 as-
say were added simultaneously with HTT103Q induction, and
the number of aggregates was recorded 48 hours after the
induction of mutant HTT fragment expression, the point at
which maximal HTT expression occurs based upon GFP sig-
nal and a steady-state rate of aggregate formation is observed
(Fig. 3b).
Of the seven compounds tested, only deferoxamine and
oligomycin significantly altered the formation of HTT103Q-
containing inclusion bodies (Fig. 3c, d). Deferoxamine treat-
ment yielded a dose-dependent reduction in the number and
the intensity of GFP-tagged HTT103Q aggregates in PC12
cells. While no effect was observed at 5 μM, a significant
reduction in aggregation was observed at 10 and 50 μM
(P<0.05 and P<0.01, respectively), with a maximal reduction
of ~50 % (Fig. 3d). Oligomycin also reduced the number of
HTT103Q aggregates by ~50 %, with the most robust effect
observed at the concentration of 1 μM (P<0.05) (Fig. 3d).
These data highlight that the chemicals identified by the
cMap likely have varied mechanisms of protection, as all of
the chemicals tested for effects on HTT103Q aggregation
prevented HTT103Q-induced toxicity, yet only oligomycin
and deferoxamine had a notable effect on HTT103Q
aggregation.
Chlorzoxazone and deferoxamine ameliorate
neurodegeneration in mutant HTT expressing fruit flies
We next sought to validate the cMap approach in vivo using
fruit flies expressing a mutant HTT fragment. We selected
chlorzoxazone and deferoxamine for further testing as they
were both highly protective in PC12 cells but differentially
affected mutant HTT aggregation. In addition, chlorzoxazone
and deferoxamine are currently used therapeutically in
humans as a skeletal muscle relaxant [34] and iron chelator
[35], respectively. We employed a widely studied fruit fly
model of mutant HTT toxicity, in which the human exon 1-
encoded fragment of HTT (HTT93Q exon 1) is expressed
pan-neuronally (via the elavGAL4 driver) using the
bitransgenic GAL4/UAS system [36]. These flies exhibit sev-
eral phenotypes that recapitulate HD symptoms, including
neurodegeneration, locomotor impairments, and reduced
lifespan [31, 37]. Neurodegeneration can be robustly assessed
by scoring the number of photoreceptor neurons—known as
rhabdomeres—present in the fly eye. The compound eyes of
Drosophila contain repeating units of ommatidia, each of
which contain eight rhabdomeres, seven of which are visible
via the pseudopupil assay. Newly emerged fruit flies were fed
with food containing 30, 100 or 300 μM of chlorzoxazone or
deferoxamine for 7 days. Strikingly, both compounds signifi-
cantly reduced rhabdomere degeneration in HTT93Q exon 1
flies compared to the controls (Fig. 4a, b). Deferoxamine ame-
liorated degeneration in a dose-dependent manner, with a
modest yet significant reduction in photoreceptor loss at
30 μM (P<0.01), which became more pronounced at 100
and 300 μM (P<0.001) (Fig. 4b). Chlorzoxazone significant-
ly reduced neurodegeneration in HTT93Q exon 1 flies at all
concentrations tested (P<0.001) (Fig. 4b). This work indi-
cates that these compounds confer neuroprotection in
HTT93Q exon 1 fruit flies, and provide in vivo support for
our findings in mammalian cells.
The modulation of HD gene expression divides negatively
correlated chemicals into two distinct groups
We next extracted the gene expression data for each of the
negatively correlated chemicals from the cMap database and
used hierarchical clustering to investigate their effects on HD-
induced genes. Hierachical clustering revealed two distinct
groups of chemicals, one containing chlorzoxazone, which
rescued rhabdomeres in HTT93Q exon 1 flies but had no
effect on HTT103Q aggregation in PC12 cells (Fig. 5a). The
other group contained deferoxamine and oligomycin, both of
which reduced HTT103Q aggregation in PC12 cells, with
deferoxamine also preventing rhabdomere loss in HTT93Q
exon 1 flies. This illustrates that the use of the cMap technique
in this manner can identify chemicals with similar character-
istics but differing mechanisms of action. The heatmap also
illustrates how each gene contributed to the identification of
the chemical as being negatively correlated to HD in our orig-
inal analysis above.
Discussion
Our primary aim in this study was to employ the cMap ap-
proach to predict chemicals that may protect against mutant
HTT-induced toxicity. In order to achieve this, we employed a
comprehensive microarray dataset for HD and control human
brain samples [17] to generate the HD Bgene signature.^ The
largest numbers and magnitudes of transcriptional changes
observed were present in the caudate nucleus [17] (Fig. 1a),
corresponding with evidence indicating that the caudate nu-
cleus is one of the earliest and most affected brain regions in
HD [33, 38]. However, it should be noted that as many as
50 % of the caudate nucleus neurons may be lost by grade 2
[39]—which undoubtedly contributed to the transcriptional
changes observed here. Nonetheless, the gene expression
changes showing the most extreme magnitudes of down-
regulation in HD—which have been validated by laser-
capture microdissection—indicate these likely reflect alter-
ations in expression at the mRNA/cell level [17].
The cMap database was queried with the gene signature
derived from the human HD data. There is an obvious discon-
nect between the characteristics of neuronal cells in vivo and
the cultured immortalized cells used to construct the cMap
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database. However, in both cases, the disease/chemical in-
duced gene expression was compared with a precise control,
therefore minimizing the contribution of cell-specific gene
expression. Differing cell machinery would still influence
the transcriptional response to a disease or chemical stimulus.
Despite this, it was recently demonstrated using the cMap that
a gene expression profile for skeletal muscle atrophy generat-
ed from mouse muscle tissue was able to identify ursolic acid
as a compound whose transcriptomic effect was inversely cor-
related to that of disease, and which subsequently was found
to reduce muscle atrophy in this mouse model [30]. This not
only demonstrates the potential of the cMap to identify con-
nections between diseases and chemicals across the in vivo/in
vitro boundary, but also with differences in time course and
species.
We hypothesized that the HD gene signature reflected a
mixture of gene expression changes due to mutant HTT tox-
icity as well as protective cellular response(s). Therefore, both
positively and negatively correlated chemicals were selected
in an unbiased manner and screened for effects on mutant
HTT fragment toxicity. Of the 12 positive chemical connec-
tions—whose expression signatures correlated with those of
HD—none significantly reduced HTT103Q toxicity. In con-
trast, 7 of the 12 chemicals whose expression signatures neg-
atively correlated with those of HD significantly reduced
HTT103Q-induced caspase activation (Fig. 2). Here, the pos-
itively correlated group of chemicals also serves as a control to
emphasize that the negatively correlated chemicals are truly
enriched for protective characteristics. These data suggest that
several of the corresponding genes in the HD signature reflect
the toxicity of mutant HTT, corroborating the idea that signif-
icant transcriptional changes observed in the human HD gene
signature are caused by the dysfunction of functionally impor-
tant transcription factors [40, 41].
The role of HTT aggregates in HD pathogenesis is contro-
versial. There is evidence that HTT aggregates cause cellular
stress and cell death by apoptosis [9], as well as conferring a
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Fig. 4 Deferoxamine and
chlorzoxazone ameliorate
neurodegeneration in flies
expressing a mutant HTT
fragment. Drosophila expressing
HTT93Q exon 1 pan-neuronally
were exposed to either
deferoxamine or chlorzoxazone
in their food at the concentrations
shown for 7 days. Rhabdomeres
were scored via the pseudopupil
assay. a Representative images of




rhabdomere number in HTT93Q
exon 1-expressing flies. Data
represent the mean rhabdomere
count per ommatidium±SEM
(N=12). **P<0.01, ***P<0.001
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either increase or decrease HTTaggregation have been shown
to be cytoprotective [24]. Nonetheless, aggregation of mutant
HTT is an important hallmark of HD pathology that provides
insight into pathogenesis. With this in mind, we tested wheth-
er seven chemicals that reduced HTT103Q toxicity in PC12
cells could modulate HTT103Q aggregation, and found that
both oligomycin and deferoxamine significantly reduced
HTT103Q aggregation (Fig. 3). Oligomycin is an inhibitor
of ATP synthase (complex V) that utilizes the mitochondrial
membrane proton gradient to convert ADP to ATP [42].
Oligomycin, as well as other metabolic inhibitors, have previ-
ously been shown to rescue cell death in HDmodels [43]. It is
thought that such inhibitors reduce cell death by activating the
pro-survival ERK and AKT pathways [43]. Although the abil-
ity of oligomycin to rescuemutant HTT-induced cell death has
previously been documented, its effect on mutant HTT aggre-
gation has not. Unfortunately, oligomycin is extremely toxic
in vivo in mammals, causing metabolic acidosis and nephro-
toxicity [44]. Thus, while the identification of oligomycin via
the cMap validates this approach, it would not represent a
viable therapeutic compound.
Deferoxamine (or desferal) is a bacterial siderophore with a
high affinity for iron and has antioxidant properties [45],
which is used therapeutically as an iron-chelating agent.
Short exposure to deferoxamine is an effective treatment for
acute iron overdose [46] and is used as a longer-term treatment
for patients with blood transfusion-related iron overload [47].
Deferoxmine has also been used to protect against both
lipopolysaccharide- and doxorubicin-induced toxicity [48,

























































































































































































































































































Reduce caspase cleavage Reduce Aggregation Reduce Rhabdomere loss
Fig. 5 Scheme indicating that a
gene expression pattern for HD
can be used to identify chemicals
that ameliorate mutant HTT
fragment-mediated cell damage. a
Hierachical clustering of the
effect of each negatively
correlated chemical on HD-
induced genes reveals two distinct
clusters of chemicals. Protective
chemicals are contained within
both clusters, with those effecting
aggregation in the lower cluster.
This highlights how the cMap can
identify chemicals with multiple
modes of action that protect
against mutant HTT toxicity. The
data was extracted from the cMap
database and was clustered by
Pearson correlation. b A human-
derived gene expression profile




in vitro and in vivo, both with and
without affecting aggregation,
thus indicating the detection of
protective chemicals with
different mechanisms of action
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an important role. Oxidative stress has been implicated in
mutant HTT-induced toxicity, with lipid peroxidation prod-
ucts such as malondialdehyde observed in HD-affected re-
gions of the brain [50]. Here, we found that deferoxamine
reduced mutant HTT toxicity and aggregation in the PC12 cell
model, and as well as ameliorating neurodegeneration in mu-
tant HTT-expressing flies. This complements previous work
showing HTT inclusion bodies contain iron, and chelators
such as deferoxamine alter aggregate dynamics [51] and are
neuroprotective. This suggests that deferoxamine is effective
upstream of HTT-aggregation but may also be protective due
to its antioxidant properties, similar to our positive control,
ebselen.
Chlorzoxazone significantly reduced HTT-induced caspase
activation in PC12 cells and rhabdomere loss in flies express-
ing HTT93Q exon 1, while having no effect on HTT aggre-
gation. Chlorzoxazone is a clinically used skeletal muscle re-
laxant which relieves discomfort due to muscle spasm [52].
Previous work has suggested that chlorzoxazone reduces ex-
citatory neurotransmission by modulating calcium-activated
SK potassium channels [53]. Interestingly, chlorzoxazone
has been proposed to counteract the neurologic effects of
CACNA1A mutations [54]. Chlorzoxazone also has anti-
inflammatory properties [55], which may also be relevant
for HD, where neuroinflammation has been heavily implicat-
ed [56].
In this study, we have thus validated the effectiveness of the
cMap approach to establish therapeutic relationships between
chemicals and HD based upon gene expression profiles. We
have demonstrated that by using a gene signature for HD, the
cMap can identify potential therapeutic agents with a hit rate
that far surpasses typical phenotypic screens. Excitingly, we
were able to identify protective chemicals with multiple
modes of action, a feature that would have been missed in a
phenotypic screen of mutant HTT fragment aggregation
alone. It is also noteworthy that the multidimensionality of a
whole genome gene expression assay allows the identification
of chemicals for multiple characteristics—meaning the same
data could be used for multiple disease screens. Thus, this
work serves as a proof of concept for such screens to be ex-
tended to other diseases where transcriptional dysregulation is
pivotal, and also for further HD-related screens to be carried
out with larger gene-expression datasets (Fig. 5), for instance
in mutant-HTTexpressing cell lines. Indeed, a greatly expand-
ed version of the cMap database is soon to be released to the
scientific community which utilizes the L1000 gene expres-
sion measurement method (http://www.broadinstitute.org/
LINCS/). The database will be dramatically enlarged from
~6000 profiles for 1300 chemicals in four cell lines, to
~576,000 profiles for 4000 chemicals, 9000 gene
knockdowns and 3000 gene overexpressions in ten cell
lines. Thus, it is clear that the power of the cMap to identify
chemicals/genes that modulate disease phenotypes will be
greatly increased. The work presented here also forms a strong
rationale for the inclusion of a database with mutant HTT-
expressing cell treatments in future cMap iterations. This
new resource—combined with the interrogation of additional
gene expression data sets at multiple pathological stages for
HD and other diseases—will provide a powerful tool for iden-
tification of candidate therapeutic chemicals for these
disorders.
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